Commentary - (2025) Volume 10, Issue 5
Received: 01-Oct-2025, Manuscript No. jomp-26-185123;
Editor assigned: 03-Oct-2025, Pre QC No. P-185123;
Reviewed: 17-Oct-2025, QC No. Q-185123;
Revised: 22-Oct-2025, Manuscript No. R-185123;
Published:
29-Oct-2025
Citation: Gutierrez, Andres. ”DLBCL’s Immune Evasion: Checkpoints, Microenvironment, and Presentation.” J Oncol Med and Pract 10 (2025):325.
Copyright: © 2025 Gutierrez A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Diffuse Large B-cell Lymphoma (DLBCL) exhibits remarkable adeptness in evading the host immune system. This sophisticated evasion is orchestrated through a variety of intricate mechanisms, many of which involve the deliberate dysregulation of crucial immune checkpoints. Among these, the PD-1/PD-L1 pathway stands out as a prominent target exploited by DLBCL cells to subvert anti-tumor immune responses and establish an immunosuppressive tumor microenvironment (TME). DLBCL cells actively manipulate their surroundings, fostering an environment that actively hinders immune surveillance and effector function. Furthermore, these malignant cells possess the capacity to diminish the expression of molecules essential for antigen presentation, thereby rendering themselves less conspicuous to cytotoxic T cells, a key component of adaptive immunity. The multifaceted nature of these immune evasion tactics necessitates a thorough understanding for the successful development of next-generation immunotherapies that can effectively overcome these defenses [1].
The PD-1/PD-L1 axis represents a critical checkpoint within the immune system, and its aberrant activation is a hallmark of many cancers, including DLBCL. The upregulation of PD-L1, observed on both lymphoma cells and within the broader TME, directly impedes T-cell activation and compromises their effector functions. This interaction is a significant contributor to the immune escape observed in DLBCL, allowing the tumor to proliferate unchecked. Consequently, targeting this pathway with immune checkpoint inhibitors has emerged as a promising therapeutic strategy, though the development of resistance mechanisms continues to pose a considerable challenge in achieving durable responses [2].
The tumor microenvironment (TME) in DLBCL is a complex ecosystem, frequently characterized by a dense infiltration of immunosuppressive cell populations. Notably, myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs) are abundant within the DLBCL TME. These cellular components actively secrete immunosuppressive cytokines, such as transforming growth factor-beta (TGF-beta) and interleukin-10 (IL-10), which collectively create an environment highly inimical to effective anti-tumor immunity. Therefore, therapeutic strategies that aim to reprogram the TME are considered essential for amplifying the efficacy of current and future treatments [3].
A common and effective immune evasion strategy employed by DLBCL cells involves the downregulation of MHC class I molecules on their surface. This reduction in MHC class I expression significantly impairs the presentation of tumor-associated antigens to CD8+ cytotoxic T lymphocytes, effectively rendering the tumor 'invisible' to these critical immune effectors. This impairment in antigen presentation can be attributed to various factors, including genetic mutations or epigenetic modifications that directly affect the expression of MHC genes and related molecules involved in the antigen processing and presentation machinery [4].
Beyond the well-studied PD-1 axis, other co-inhibitory receptors on T cells also contribute to immune suppression within the DLBCL TME. The expression of receptors such as CTLA-4, while perhaps less frequently targeted than PD-1 in clinical practice, plays a significant role in dampening T-cell responses. A comprehensive understanding of the intricate interplay between these multiple inhibitory pathways is therefore vital for the design of more effective combination immunotherapies that can comprehensively disarm the tumor's immune-suppressing arsenal [5].
Tumor-associated macrophages (TAMs) are another crucial cellular component of the TME that can influence anti-tumor immunity. While TAMs can exhibit plasticity and adopt diverse roles, in DLBCL, they frequently differentiate into an immunosuppressive M2 phenotype. These M2 TAMs actively promote tumor growth and survival by secreting immunosuppressive cytokines and factors that support angiogenesis, further contributing to the overall immune-resistant nature of the lymphoma and its ability to evade immune detection and destruction [6].
Genetic alterations within DLBCL cells can directly impact their ability to evade immune responses. Specific mutations affecting genes crucial for antigen processing and presentation pathways are frequently observed. Additionally, alterations in genes that encode components of signaling pathways regulating immune responses can also lead to a more immunosuppressive cellular phenotype. Understanding the genomic landscape of DLBCL is therefore critical for identifying new vulnerabilities that can be exploited therapeutically [7].
B-cell receptor (BCR) signaling within DLBCL cells plays a significant role in promoting their survival and proliferation. This intrinsic signaling often operates in concert with signals originating from the TME, creating a pro-survival niche for the malignant cells. Consequently, modulating BCR signaling pathways represents a potential therapeutic avenue to overcome resistance to immunotherapies and enhance anti-tumor immune responses. Targeting this fundamental pathway could disrupt the lymphoma's ability to thrive and evade immune destruction [8].
The aberrant expression of non-coding RNAs, particularly microRNAs (miRNAs), has been increasingly recognized as a significant factor in DLBCL pathogenesis and immune evasion. These miRNAs can modulate the expression of numerous genes involved in critical processes such as antigen presentation, immune cell function, and the overall composition of the TME. By targeting these genes, miRNAs contribute to the establishment of a more tolerogenic and immunosuppressive tumor microenvironment, hindering effective anti-tumor immunity [9].
Epigenetic modifications, encompassing processes like DNA methylation and histone modifications, exert a profound influence on the immune landscape of DLBCL. These alterations can lead to the aberrant silencing of genes that are essential for mounting an effective anti-tumor immune response or, conversely, the activation of genes that actively promote immune suppression. This epigenetic reprogramming offers promising avenues for therapeutic intervention, as targeting these mechanisms could potentially restore immune recognition and effector function against DLBCL [10].
Diffuse Large B-cell Lymphoma (DLBCL) employs sophisticated immune evasion strategies to escape host surveillance. These mechanisms often involve the dysregulation of key immune checkpoints, such as PD-1/PD-L1, and the manipulation of the tumor microenvironment (TME) to foster an immunosuppressive milieu. DLBCL cells can also actively downregulate antigen presentation machinery, making them less visible to cytotoxic T cells. Understanding these multifaceted evasion tactics is crucial for developing more effective immunotherapies [1].
The PD-1/PD-L1 axis is a critical immune checkpoint frequently exploited by DLBCL. Upregulation of PD-L1 on lymphoma cells and within the TME can directly inhibit T-cell activation and function, contributing significantly to immune escape. Targeting this pathway with immune checkpoint inhibitors has shown promise, although resistance mechanisms remain a significant challenge [2].
The tumor microenvironment (TME) in DLBCL is often characterized by a dense infiltration of immunosuppressive cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). These cells secrete cytokines like TGF-beta and IL-10, which create an environment hostile to anti-tumor immunity. Strategies aimed at reprogramming the TME are essential for enhancing therapeutic responses [3].
Downregulation of MHC class I molecules on DLBCL cells is a common strategy to avoid recognition by CD8+ cytotoxic T lymphocytes. This impairment in antigen presentation can be mediated by genetic mutations or epigenetic modifications affecting the expression of MHC genes and associated molecules, rendering the tumor 'invisible' to the immune system [4].
The expression of co-inhibitory receptors on T cells, beyond PD-1, such as CTLA-4, is also implicated in immune suppression within the DLBCL TME. While less frequently targeted than PD-1, understanding the interplay of these multiple inhibitory pathways is vital for developing combination immunotherapies [5].
Tumor-associated macrophages (TAMs) play a dual role in cancer, but in DLBCL, they often adopt an immunosuppressive M2 phenotype. These TAMs can promote tumor growth and survival by secreting immunosuppressive cytokines and factors that support angiogenesis, contributing to the overall immune-resistant nature of the lymphoma [6].
Genetic alterations in DLBCL can directly influence immune evasion. For instance, mutations affecting genes involved in antigen processing and presentation, or those encoding components of signaling pathways that regulate immune responses, can lead to a more immunosuppressive phenotype [7].
B-cell receptor (BCR) signaling in DLBCL can also contribute to immune evasion by promoting cell survival and proliferation, often in conjunction with signals from the TME. Modulating BCR signaling pathways could be a viable strategy to overcome resistance to immunotherapy [8].
The aberrant expression of non-coding RNAs, such as microRNAs (miRNAs), has been observed in DLBCL and can influence immune evasion. These miRNAs can target genes involved in antigen presentation, immune cell function, and TME composition, contributing to a more tolerogenic environment [9].
Epigenetic modifications, including DNA methylation and histone modifications, play a significant role in shaping the immune landscape of DLBCL. These alterations can lead to the silencing of genes critical for anti-tumor immunity or the activation of genes that promote immune suppression, offering potential targets for therapeutic intervention [10].
Diffuse Large B-cell Lymphoma (DLBCL) employs complex immune evasion strategies, including dysregulation of immune checkpoints like PD-1/PD-L1 and manipulation of the tumor microenvironment (TME) to create an immunosuppressive milieu. DLBCL cells can also downregulate antigen presentation machinery, making them less visible to cytotoxic T cells. The PD-1/PD-L1 axis is a key pathway exploited by DLBCL, where its upregulation inhibits T-cell function. The TME is often infiltrated by immunosuppressive cells like MDSCs and Tregs, which secrete cytokines that hinder anti-tumor immunity. Downregulation of MHC class I molecules is another evasion tactic, impairing antigen presentation to T cells. Other co-inhibitory receptors like CTLA-4 also contribute to immune suppression. Tumor-associated macrophages (TAMs) in DLBCL often adopt an immunosuppressive M2 phenotype, promoting tumor growth and survival. Genetic alterations and aberrant expression of non-coding RNAs like miRNAs further contribute to immune evasion. Epigenetic modifications also play a significant role in shaping the immune landscape, impacting genes critical for anti-tumor immunity. Modulating BCR signaling pathways is also being explored as a strategy to overcome therapeutic resistance.
None
None
Journal of Oncology Medicine & Practice received 142 citations as per Google Scholar report
